10 ms·
Launch HN: Atomic Alchemy (YC W19) – Manufacturing Nuclear Medicine
Hello, HN.
I’m Thomas Eiden, founder of Atomic Alchemy.
Atomic Alchemy will manufacture nuclear medicine and the radioactive materials used to make it, using several compact nuclear reactors.
These will be the first privately-owned nuclear reactors for nuclear medicine production. They are merely higher-powered versions of previously-licensed reactor designs that currently reside at universities. These reactor designs are passively safe and cannot melt down. With improvements in modeling and simulation that have occurred in the last few years, it is quicker and cheaper than ever to license and construct such a facility. But to be clear—we won’t be manufacturing reactors—we’ll be a chemical/drug manufacturer in the same way that Delta Airlines doesn’t manufacture planes or airports, but is a transportation company.
Before starting Atomic Alchemy, I was the lead reactor core designer at the Advanced Test Reactor at Idaho National Laboratory. My main job each operating cycle was to arrange the reactor core in such a way to allow the United States Nuclear Navy to run successful material experiments for their next generation submarines and aircraft carriers. I’ve always been interested in production and efficiency, and the issues currently plaguing nuclear medicine production have been of great interest to me all the way back to when I operated a reactor in college.
Nuclear medicine is used in a wide variety of diagnostic imaging procedures and cancer treatments. The most common procedure is the radiocardiogram to diagnose cardiological issues, and brachytherapy for cancer treatment.
Unbeknownst to many, there is a critical shortage of nuclear medicine worldwide--right now. The main failure in the supply chain is the fact that the entire world’s feedstock for nuclear medicine primarily comes from six government-run reactors, most of which are over 45 years old and will be retired in the next 10 years. Additionally, these government-run reactors are scientific research reactors and are not set up to efficiently produce these materials.
I have a design for a manufacturing facility that combines the entire supply chain, from irradiation, to chemical purification, to medicine production. This will allow Atomic Alchemy to fill the void as more aging reactors are shut down and allow those that remain to focus on their true purpose—science.
Currently, the reactors, chemical purification, and pharmaceutical manufacturing facilities are all in separate facilities, sometimes oceans apart. By shrinking the entire supply chain into a single facility, manufacturing costs can be slashed by up to 50%, as regulatory, shipping, and myriad other costs associated with the radioactive material decaying in transit, is reduced.
The market for radioactive feedstock alone is well over a one billion dollar market worldwide, and is constrained by the current supply. As the standard of living abroad continues to improve, developing markets will demand even more nuclear medicine.
Looking forward to your feedback and questions.
- arciini 8y agoThis is pretty cool! I worked for a summer at Chalk River in Canada, and it was crazy that a few suppliers could produce so much of the world's medical isotopes. I remember reading about fears of a Technetium-99 shortage when it does shut down [1]. People are very hesitant about nuclear power, but medical isotope manufacturing requires little enough nuclear fuel that it should be very safe. You sound like the right person to tackle this, and the market is definitely there. Good luck! 1. https://www.nature.com/news/reactor-shutdown-threatens-world-s-medical-isotope-supply-1.20577 https://www.nature.com/news/reactor-shutdown-threatens-world...
- atomicalchemy 8y agoThank you for the comment and well wishes. Chalk River shutting down was a huge blow to production capacity, as it alone supplied about 20% of the world's demand for radioisotopes. In fact, Chalk River shut down in 2016, but the license was extended for two years to keep it on hot standby solely because of its importance to nuclear medicine supply. When they finally permanently shut it down in March of 2018, I believe the reactor was over 61 years old! You can find articles like this at least once a year, warning of the next shortage: https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/nuclear-imaging-labs-brace-tc-99m-shortage https://www.cardiovascularbusiness.com/topics/cardiovascular...
- philipkglass 8y agoThe reactor power sounds like it is in the range of TRIGA and you have a video of a TRIGA reactor on your FAQ page. It looks like you are planning to use a TRIGA design. Is that right? NorthStar has started producing Mo-99 in accelerators without fissioning targets. Other producers may start soon: Competitors abound to produce key medical isotope After decades with no US producer, a plethora of hopefuls vie for a share of the molybdenum-99 market. https://physicstoday.scitation.org/do/10.1063/PT.6.2.20190221a/full/ https://physicstoday.scitation.org/do/10.1063/PT.6.2.2019022... Your FAQ says "As a private, production-oriented company, we intend to vertically integrate much of the radioisotope process to reduce inefficiencies and build a modular facility that can be expanded as a stable supply of radioisotopes encourages their use and increases demand." How much demand elasticity do you foresee, if Atomic Alchemy and competitors can easily produce more Mo-99 than was historically consumed?